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ABSTRACT
ObjeCtive
To determine whether the addition of data derived 
from magnetic resonance imaging (MRI) of the brain to 
a model incorporating conventional risk variables 
improves prediction of dementia over 10 years of 
follow-up.
Design
Population based cohort study of individuals aged ≥65.
setting
The Dijon magnetic resonance imaging study cohort 
from the Three-City Study, France.
PartiCiPants
1721 people without dementia who underwent an MRI 
scan at baseline and with known dementia status over 
10 years’ follow-up.
Main OutCOMe Measure
Incident dementia (all cause and Alzheimer’s disease).
results
During 10 years of follow-up, there were 119 confirmed 
cases of dementia, 84 of which were Alzheimer’s 
disease. The conventional risk model incorporated age, 
sex, education, cognition, physical function, lifestyle 
(smoking, alcohol use), health (cardiovascular disease, 
diabetes, systolic blood pressure), and the 
apolipoprotein genotype (C statistic for discrimination 
performance was 0.77, 95% confidence interval 0.71 to 
0.82). No significant differences were observed in the 
discrimination performance of the conventional risk 
model compared with models incorporating data from 
MRI including white matter lesion volume (C statistic 
0.77, 95% confidence interval 0.72 to 0.82; P=0.48 for 
difference of C statistics), brain volume (0.77, 0.72 to 
0.82; P=0.60), hippocampal volume (0.79, 0.74 to 0.84; 
P=0.07), or all three variables combined (0.79, 0.75 to 
0.84; P=0.05). Inclusion of hippocampal volume or all 
three MRI variables combined in the conventional 
model did, however, lead to significant improvement in 
reclassification measured by using the integrated 
discrimination improvement index (P=0.03 and P=0.04) 
and showed increased net benefit in decision curve 
analysis. Similar results were observed when the 
outcome was restricted to Alzheimer’s disease.
COnClusiOns
Data from MRI do not significantly improve 
discrimination performance in prediction of all cause 
dementia beyond a model incorporating demographic, 
cognitive, health, lifestyle, physical function, and 
genetic data. There were, however, statistical 
improvements in reclassification, prognostic 
separation, and some evidence of clinical utility.
Introduction
The prevalence of dementia is expected to double every 
20 years, with about 35.6 million people worldwide 
affected in 2010 and 65.7 million predicted in 2030.1  The 
greatest increase is expected in the developing world. 
Despite the lack of an effective treatment for Alzhei-
mer’s disease, it is estimated that a two year delay in 
onset could have a dramatic effect on its prevalence, 
reducing incidence by about 20%.2  Risk assessment for 
future disease to better focus intervention to those at 
highest risk and reduce the cost of unnecessary diag-
nostics is therefore a major issue, and it has been the 
aim of many recent studies.3 4-7 In that regard, the devel-
opment of a simple accurate method for prediction of 
risk of dementia is a priority.
Having an accurate model for predicting future 
dementia in population based settings would be bene-
ficial for several reasons. Firstly, targeting whole popu-
lations for modification of behaviour and reduction of 
risk factors might not always be cost effective, particu-
larly when intervention strategies are costly or adher-
ence rates low. Secondly, broad based targeting 
strategies are not always recommended— for example, 
when there are safety concerns or a high risk of side 
effects of treatment. A complementary approach could 
be to target high risk individuals by developing a model 
to accurately identify these individuals as early as pos-
sible without being too broad in risk selection. These 
individuals could then be referred for services, 
improved care, clinical trials, and, when intervention is 
available, stratified or individualised risk factor reduc-
tion to ultimately improve patient outcomes. In contrast, 
WhAT IS AlReAdy knoWn on ThIS TopIC
Accurate identification of individuals at high risk of dementia is important to 
improve diagnostic and therapeutic protocols
Prediction of risk has conventionally been based on sociodemographic, 
neuropsychological, health, lifestyle, physical function, and genetic variables. 
Novel variables also include information from MRI of the brain 
The incremental contribution to prediction models of MRI variables compared with 
more simple prediction variables on the population level remains unclear
WhAT ThIS STudy AddS
Addition of MRI variables, including white matter lesion, brain, and hippocampal 
volumes (or all three variables combined), to a risk model incorporating 
conventional risk variables did not result in significant improvement in 
discrimination for incident dementia (all cause or Alzheimer’s disease) over a 10 
years’ follow-up
More accurate risk classification (measured with the integrated discrimination 
improvement index) and prognostic separation (measured with the D statistic) was 
observed when hippocampal volume or all three MRI variables combined were 
added to the conventional risk model
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people at low risk could be excluded from further 
 immediate follow-up thereby reducing costs, for example, 
of unnecessary diagnostics.
While ageing is the most universally accepted risk 
factor for dementia, other conventional risk factors 
have been incorporated into prediction models devel-
oped in populations aged ≥65, including poor neuro-
psychological test performance, subjective memory 
complaint, low educational attainment, sex, depres-
sion, history of cardiovascular (such as coronary heart 
disease, peripheral vascular disease), cerebrovascular 
(such as stroke), and metabolic (such as diabetes) dis-
eases and their risk factors (such as hypertension, 
smoking, alcohol use, physical inactivity, obesity), 
blood based biomarkers (serum total cholesterol con-
centration), inability to perform activities of daily living 
(such manage money and drugs), and genetic suscepti-
bility (such as apolipoprotein e4 status).8-19  Non- 
traditional risk factors (such as denture fit and eye and 
ear trouble) have also been used.20 21  Predictive accuracy 
of current models has generally been low to moderate.7
Improvement in dementia risk prediction is needed 
for medical and research purposes to enhance diag-
nostic protocols (such as recruitment into clinical 
 trials) and inform therapeutic decisions (such as per-
sonalised medicine). This could be achieved through 
the use of indicators of dementia derived from mag-
netic resonance imaging (MRI), including structural 
changes (such as hippocampal atrophy, medial tem-
poral lobe atrophy, and evidence of white matter dis-
ease) and functional changes (such as positron 
emission tomography imaging of amyloidosis and 
tauopathy), in addition to assessment of cerebral spi-
nal fluid (such as amyloid-β 42 and tau). Variables 
derived from both cerebral spinal fluid analysis and 
MRI have been proposed for stratification of patients 
for research purposes under the new “lexicon” of Alz-
heimer’s disease.22-24 The immediate implications of 
using such complex biomarkers are that they require 
technologically advanced, costly, burdensome (for 
participants as they can cause discomfort), and not 
easily available methods, especially in developing 
countries. This might offset any advantage of the use 
of such variables in predictive models. To make rec-
ommendations on the use of data from MRI in demen-
tia risk prediction in population based settings, we 
need evidence on what this adds to more convention-
ally derived risk models.
We evaluated the value of markers from MRI added to 
a model incorporating previously proposed conven-
tional risk factors for the prediction of all cause demen-
tia and Alzheimer’s disease over 10 years’ follow-up in 
a large prospective population based cohort study.
Methods
sample
The Three City Study is a multi-centre longitudinal pop-
ulation based cohort study, conducted in three French 
cities (Bordeaux, Dijon, and Montpellier), and designed 
to estimate the risk of dementia and cognitive impair-
ment attributable to vascular factors. Full details of the 
methods and baseline characteristics of the participants 
have been published previously.25
The current study is solely based on the Dijon centre, 
the only centre in which a cerebral MRI was conducted. 
In brief, at the 1999 French census, the total population 
of Dijon was 153 800.26 To be eligible for recruitment a 
person had to be living in Dijon or its suburbs, regis-
tered on the electoral roll, aged ≥65, and not be living in 
an institution. Baseline interviews were undertaken in 
1999-2001, with follow-up interviews conducted about 
two, four, six, and 10 years after enrolment.
From the original 4931 participants enrolled in Dijon, 
MRI was offered to those aged 65-80 who had been 
enrolled between June 1999 and September 2000. 
Although the consent rate for scanning was 83%, scans 
were obtained from 1923 participants (39%), as funding 
restrictions precluded MRI for everyone. From these 
1923 participants we excluded from analysis 123 individ-
uals with missing MRI variables (such as poor scan 
quality and artefacts), eight with prevalent dementia, 
and individuals with missing dementia status over the 
10 years of follow-up (n=71 participants were seen only 
at baseline). The remaining sample included 1721 indi-
viduals. Follow-up time ranged from 0.6 to 10.6 years 
(mean 7.3 years, SD 2.3 years).
Comparison of the baseline characteristics of our 
analytical sample with all remaining age eligible 
 participants without dementia in Dijon is shown in 
appendix 1. Individuals excluded because of missing 
dementia status at follow-up did not differ from those 
included with regard to sex (χ2=0.53, df=1, P=0.47), age 
(F1,1790=0.97, P=0.97), or educational attainment 
(χ2=1.92, df=1, P=0.38). Individuals without known 
dementia status over follow-up, however, performed 
significantly worse on the mini-mental state examina-
tion at baseline: median score 28 (interquartile range 
27-29) for included v 27 (26-29) for excluded; Wilcox-
on-Mann-Whitney test: z=2.42, P=0.02.
Patient involvement
There was no patient involvement in the design, con-
duct, and interpretation of the study.
baseline assessments
Trained psychologists collected data with a stan-
dardised questionnaire during a face to face interview 
at the participants’ home. Information included socio-
demographic status, lifestyle, medical history, drug 
use, and assessment of cognitive and functional status. 
Clinical examination included measurements of blood 
pressure with a digital tensiometer (OMRON M4). 
Anthropometric measures included height and weight. 
Fasting bloods samples were taken and markers (such 
as cholesterol, glucose) measured at a single laboratory.
Magnetic resonance imaging
Brain MRI scanning was undertaken on average of 4.2 
months (SD 3.0 months) after the baseline examination. 
Scanning was completed with a 1.5-Tesla Magnetom 
(Siemens, Erlangen, Germany). Usual MRI exclusions 
were applied. The scanning sequence and data 
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extraction methods have been described in detail previ-
ously.27  28  In brief, raw data were converted to the ACR-
NEMA standard format and then transformed for 
analysis and storage at the Department of Neurofunc-
tional Imaging, Caen.25  This centre developed fully auto-
matic image processing software for tissue  segmentation 
and to detect and quantify white matter lesions.27  29 
Automated imaging processing was also used to study 
brain volume (white matter, grey matter, and ventricles). 
Total intracranial volume by summing grey  matter, 
white matter, and cerebral spinal fluid  volumes were 
computed with voxel based morphometry  techniques.
We selected three MRI measures for analysis includ-
ing white matter lesion volume (calculated by summing 
the volumes of all white matter lesions detected), hip-
pocampal volume (combining left and right sides), and 
total brain volume (defined as the sum of grey and 
white matter) as these are commonly assessed and have 
been previously associated with cognitive decline and 
dementia.30-33 All three MRI variables were normalised 
to total intracranial volume and converted to a percent-
age—that is, each volume (white matter lesion, hippo-
campal, and whole brain) was divided by total 
intracranial volume and multiplied by 100.
Both the total brain volume and hippocampal volume 
variables were normally distributed. In contrast, white 
matter lesion volume had a markedly skewed distribu-
tion and therefore scores were log transformed before 
analysis to decrease the impact of extreme observations.
Diagnosis of dementia 
Diagnosis of dementia was established with a three 
phase procedure. All participants were first screened 
with scores from the mini-mental state examination34 
(with education adjusted cut-off points) and the Isaac 
set test.35  In Dijon, in the second phase, a neurologist 
saw individuals with suspected incident dementia 
based on their performance on neuropsychology tests. 
In the third phase, a panel of independent neurolo-
gists reviewed all potential prevalent and incident 
cases to obtain consensus on diagnosis and aetiology 
according to the criteria of the Diagnostic and Statisti-
cal Manual of Mental Disorders, fourth edition.36  With 
regard to subtypes of dementia, Alzheimer’s disease 
(possible and probable) was diagnosed according to 
criteria from the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzhei-
mer’s Disease and Related Disorders Association 
(NINCDS-ADRDA), and vascular dementia was based 
on history of vascular disease, Hachinski score, and 
MRI (whenever possible).25 37
Potential predictors
Information on prognostic determinants of occurrence 
of dementia was extracted from the published literature 
on dementia risk prediction and previous findings from 
the Three City Study. We selected 13 variables. Sociode-
mographic factors included age, sex, and educational 
attainment. Lifestyle factors included smoking and 
alcohol use. Functional assessment was measured with 
the Lawton and Brody scale for instrumental activities 
of daily living38  that assesses ability to use the 
 telephone, responsibility for drug treatment, managing 
money, mobility, shopping, grooming, housework, and 
laundry (the last three were asked in women only). Cog-
nition was assessed with the mini-mental state exam-
ination, Benton visual retention test,39  and the digit 
span test.40 Appendix 2 shows the adjusted cut-off 
scores for cognitive impairment adjusted for age and 
education. Health variables included cardiovascular 
events (combining self reported history of myocardial 
infarction, coronary surgery, coronary angioplasty, sur-
gery of the arteries in the legs, or stroke requiring 
admission to hospital), metabolic disease (diabetes; 
self reported, high glucose concentration ≥7.0 mmol/L, 
or receipt of hypoglycaemic treatment including oral 
diabetic drugs or insulin), and systolic blood pressure 
(continuous). Genetic risk assessed apolipoprotein e4 
status (coded as e4 positive v e4 negative).
Missing covariate information
Of the 1721 participants included in the analysis, few 
had missing information on covariates (<2.5%; range 
0-2.4%). In total, 87 participants had missing informa-
tion on covariates in the conventional prediction 
model, which was run on 1634 participants.
statistical analyses
We tested differences in demographics between the 
groups with and without dementia using χ2 test (for cat-
egorical variables), analysis of variance (for continuous 
normally distributed variables), or the Wilcox-
on-Mann-Whitney test (for continuous, non-normally 
distributed variables). Data were censored at first diag-
nosis of dementia (for dementia cases) or last follow-up 
interview (for those without dementia).
A multivariable model incorporating all 13 conven-
tional risk variables was calculated with Cox propor-
tional hazards regression analysis. To test whether MRI 
data improve discrimination performance of this 
model, we performed Cox regression analyses with 
inclusion of each of the MRI variables and their combi-
nation. The proportional hazards assumption was 
tested with the estat phtest command in Stata and was 
not violated in any model (test carried out with the 
detail option in Stata to examine the proportional haz-
ards assumption for each predictor as well as to carry 
out the global test). Non-linearity of the three MRI vari-
ables was checked visually by plotting the martingale 
residuals41 and statistically by using a Wald test (using 
the Stata command nlcheck, with the spline option). 
There was no evidence of non-linearity.
For each model we obtained estimates of Harrell’s con-
cordance index (with 95% confidence intervals, calcu-
lated by bootstrapping) using the method described by 
Newson.42  Inference regarding improvement of the mod-
els incorporating MRI variables compared with the con-
ventional risk model was undertaken by estimating the 
difference (and 95% confidence interval) in the 
 concordance statistics using the lincom command in 
Stata. We calculated net reclassification improvement 
(with three risk groups corresponding to 0%-<10%, 
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 10%-<20%, and ≥20%) and integrated discrimination 
improvement indices to further assess model perfor-
mance.43 The net reclassification improvement index 
assesses correctness of reclassification (for example, up 
for events and down for non-events) into different pre-
specified risk categories. In contrast, the integrated dis-
crimination improvement index is a continuous measure 
that can be interpreted as the improvement in average 
sensitivity minus the change in average (1−specificity). 
The integrated discrimination improvement index has 
the advantage that it is a continuous measure and there-
fore does not depend on arbitrary user defined risk cate-
gories. For the net reclassification improvement index 
and integrated discrimination improvement index values 
above zero indicate improved risk classification with the 
addition of the new variable(s). Each index was calcu-
lated with the predstat command in Stata. We also calcu-
lated Royston and Sauerbrei’s44 index of discrimination 
(D) and optimism corrected D (Dadjusted) using the str2d 
command in Stata to assess prognostic separation. To 
assess possible clinical implications of adding the MRI 
variables to the conventional risk prediction model, we 
used the theoretical relation between the threshold prob-
ability of disease and the relative value of false positive 
and false negative results to ascertain the value of the var-
ious prediction models (decision curve analyses), 
accounting for censored observations using the stdca 
command in Stata.45 Preferred models are those with the 
highest net benefit calculated as the difference between 
the proportion of true positives and the proportion of false 
positives weighted by the relative harm of a false positive 
and false negative result. All analyses were repeated with 
Alzheimer’s disease as the outcome (sensitivity analysis).
Although the sample size is large for a brain imaging 
study, it is relatively small for risk model testing. There-
fore, instead of splitting the sample into derivation and 
testing datasets we ran the analyses on the entire sam-
ple. To correct for optimism bias in the C statistic value 
(that is, over-fitting to a specific sample), we undertook 
internal validation using 100 bootstrap samples. To use 
all the data from the 1721 participants and test whether 
missingness (assumed to be missing at random) influ-
enced the results, we carried out multivariate imputa-
tion by chained equations (using the mi procedure in 
Stata) that included all 13 conventional predictors and 
the outcome variable. We created 10 imputed datasets 
and fitted each model separately on each. Results from 
the analysis of each imputed dataset were combined 
with Rubin’s rules (mi estimate command in Stata)46 
(see appendix 3). Analyses were completed with STATA 
version 13 (StataCorp, College Station, TX). All probabil-
ities were two tailed, and significance was set at P<0.05.
Results
Demographics
Of the 1721 participants with complete MRI data at 
baseline, 119 (6.9%) progressed to dementia over the 
10 years of follow-up. The mean time to onset of 
dementia was 6.7 years (SD 2.0 years; range 1.7-10.5 
years). People without dementia were followed for an 
average of 7.4 years (SD 2.3 years; range 0.6-10.6 years). 
Table 1 shows baseline demographic characteristics of 
the cohort stratified by dementia status at follow-up. 
The groups with and without dementia differed signifi-
cantly with respect to age, education, physical func-
tion, cognitive function and apolipoprotein e4 allele 
status but had similar distributions of sex, smoking, 
alcohol, history of cardiovascular disease, diabetes, 
and systolic blood pressure.
simple model for dementia risk with conventional 
risk factors
When all 13 conventional risk variables were included 
in the model (M1), significant predictors of 10 year inci-
dent dementia included age, physical function, cogni-
tion (mini-mental state examination, Benton visual 
retention test, and digit span), and apolipoprotein e4 
allele status (table 2). The discrimination performance 
of the model was moderate (C statistic 0.77, 95% confi-
dence interval 0.71 to 0.82; n=1634).
Conventional risk factors and Mri derived variables
Table 3  summarises the performance indices including 
Harrell’s concordance index (C statistic) (and estimated 
bias), net reclassification improvement, integrated dis-
crimination improvement, and Royston and Sauer-
brei’s44  index of discrimination (unadjusted and 
adjusted) for the conventional prediction model and the 
extended models including MRI data: white matter 
lesion volume, whole brain volume, and hippocampal 
volume (table 2 shows the hazard ratios and their 95% 
confidence intervals). Across the four different models, 
optimism bias (or over-fitting) in the C statistic value 
was low (optimism ranged from: 0.0188 to 0.0285). 
While the C statistic did slightly increase with inclusion 
of MRI variables, as shown in figure 1 , the change was 
not significant (P values are shown in table 3). This indi-
cated that discrimination performance of the simple 
model as measured by the C statistic was not signifi-
cantly improved with the addition of any of the MRI 
variables, alone or in combination.
As shown in table 3, however, the integrated discrimi-
nation improvement index was positive and significantly 
different from zero, suggesting improvement in reclassifi-
cation, when the conventional model was compared with 
models incorporating all three MRI variables (integrated 
discrimination improvement 0.043; z=2.11, P=0.04) or hip-
pocampal volume (0.044; z=2.23, P=0.03). Furthermore, 
compared with the conventional model, Royston and 
Sauerbrei’s44 index of discrimination (D) was higher (dif-
ference >0.2) when all three MRI variables or hippocam-
pal volume were added to the conventional model, 
indicating an improvement in prognostic separation.
Decision curve analysis
Figure 2 shows the net benefit curves for the conven-
tional prediction model and the extended model 
includes all three MRI variables. As shown, for increas-
ing probability thresholds the models incorporating all 
three MRI variables combined had higher net benefit 
than the conventional model, suggesting that this 
model has potentially higher clinical utility. Increase in 
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net benefit was further seen when hippocampal volume 
was included to the conventional risk model (similar 
curve to the curve with all three variables) but not when 
incorporating whole brain volume and white matter 
lesion volume (figures not shown).
sensitivity analysis: predicting alzheimer’s disease
With respect to subtypes of dementia, 84 (71%) people 
had a diagnosis of possible or probable Alzheimer’s dis-
ease, 13 (11%) had mixed dementia, and the rest were 
classified as “other” (including, for example, people with 
vascular dementia). Table 4  shows the results from the 
Cox proportional hazards regression analysis, and table 
5  summarises the performance indices for the conven-
tional model, with and without MRI variables, when the 
outcome was restricted to Alzheimer’s  disease. Similar to 
the results for all cause dementia, as shown in figure 3 , 
there was a slight but non-significant improvement in 
the discriminative performance of the conventional risk 
factor model we included MRI data on hippocampal 
table 1 | baseline demographic characteristics of sample stratified by dementia status over 10 years of follow-up. Figures 
are percentage (number) of participants unless stated otherwise
variables no dementia (n=1602) Dementia (n=119) P value*
Demographics
Mean (SD) age (SD) 72.2 (4.1) 74.8 (4.0) <0.001
Sex:
 Male 39.4 (631) 38.7 (46)
0.88
 Female 60.6 (971) 61.3 (73)
Education:
 High 36.8 (590) 29.4 (35)
0.011 Intermediate 32.0 (512) 26.1 (31)
 Low (none or up to primary school) 31.2 (500) 44.5 (53)
Physical function
Totally autonomous on 5 activities (men) or 8 activities (women) 96.3 (1530) 87.2 (102)
<0.001
Dependent on at least one activity 3.7 (59) 12.8 (15)
Cognition
Mini-mental state examination†:
 Median (IQR) 28 (27-29) 27 (26-28)
 Not impaired 91.7 (1466) 79.0 (94)
<0.001
 Impaired 8.3 (133) 21.0 (25)
Benton visual retention test†:
 Median (IQR) 12 (11-13) 11 (9-12)
 Not impaired 90.1 (1433) 78.8 (93)
<0.001
 Impaired 9.9 (157) 21.2 (25)
Digit span†:
 Median (IQR) 6 (5-7) 5 (5-7)
 Not impaired 92.1 (1471) 82.2 (97)
<0.001
 Impaired 7.9 (126) 17.8 (21)
lifestyle
Smoking:
 Never 62.1 (994) 59.7 (71)
0.61
 Smoker/past 38.0 (608) 40.3 (48)
Alcohol (g/day):
 None/ex-drinker 19.9 (311) 19.0 (22)
0. 60
 ≤12 g 45.5 (712) 50.9 (59)
 13-24 g 19.4 (303) 19.0 (22)
 >24 g 15.2 (238) 11.2 (13)
Health
Diabetes:  
 No self report and glycaemia <7.0 mmol/L 91.8 (1461) 88.7 (102)
0.24
 Self report, treatment, or glycaemia ≥7.0 mmol/L 8.2 (130) 11.3 (13)
History of cardiovascular disease:
 No self report 93.8 (1503) 92.4 (110)
0.55
 Self report 6.2 (99) 7.6 (9)
Mean (SD) systolic blood pressure 148.8 (22.7) 149.6 (22.1) 0.70
genetics
Apolipoprotein e4:
 No e4 alleles 79.2 (1262) 64.7 (75)
<0.001
 ≥1 e4 alleles 20.8 (332) 35.3 (41)
Mri‡
Median (IQR) % white matter lesion volume 0.29 (0.20-0.46) 0.33 (0.21-0.63) 0.076
Median (IQR) % whole brain volume 71.7 (69.5-74.0) 70.8 (68.4-73.0) 0.001
Median (IQR) % hippocampal volume (left and right combined) 0.49 (0.46-0.52) 0.45 (0.41-0.49) <0.001
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 volume or all three MRI variables combined. Also, simi-
lar to the results for all cause dementia the integrated 
discrimination improvement index was significantly dif-
ferent from zero, and Royston and Sauerbrei’s44  index of 
discrimination (D) also increased in the models incorpo-
rating all three MRI variables and hippocampal volume. 
The decision curve analyses for the outcome Alzheimer’s 
disease shows a similar net benefit improvement when 
all three MRI variables were included in the conventional 
risk model (fig 4). A similar picture was seen when hippo-
campal volume was added to the conventional model but 
not for white matter lesion volume or whole brain vol-
ume (figures not shown).
discussion
In this large prospective population based cohort study, 
addition of MRI variables to a conventional risk model 
including sociodemographic, functional, cognitive, 
health, lifestyle, and genetic predictors did not signifi-
cantly improve discrimination performance for all 
cause dementia over 10 years’ follow-up as measured by 
the C statistic. In contrast, we found that data from MRI 
might have some value in reclassification, prognostic 
separation, and some improvement in clinical utility. 
Findings were similar when we restricted the outcome 
to Alzheimer’s disease. The results have implications 
for avoiding unnecessary increase in cost by using MRI 
for identifying individuals at high risk of dementia in 
population based settings. The results also have impli-
cations for decisions regarding the statistics used to 
evaluate risk prediction models.
Comparison with other studies
Currently there are no recommended models for screen-
ing for individuals at high risk of dementia. Numerous 
predictors have been proposed including demographic, 
neuropsychological, health, physical function, life-
style, and neuroimaging variables. Use of complex 
data, however, would be expected to increase discrimi-
natory ability. Previous studies have not compared 
whether MRI data improves prediction of dementia risk 
in the general population relative to information gained 
from simple multivariable models of conventional risk 
factors. While our results do not contradict previous 
findings of an association between MRI variables (that 
is, hippocampal and white matter lesions volumes) and 
incident dementia, they suggest that inclusion of MRI 
data to a model incorporating convention risk variables 
(such as age, education, cognitive function (memory 
and global functioning), impairments in instrumental 
activities of daily living, health (cardiovascular disease, 
diabetes, and blood pressure), lifestyle (smoking and 
alcohol use) and apolipoprotein e4 status) does not sig-
nificantly improve discrimination performance.
In contrast with comparison of the discriminatory 
 performance of the models, however, inspection of other 
C 
st
at
is
tic
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3 MRI
variables
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atrophy
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0.74
Fig 1 | C statistics (95% Ci) (not adjusted for optimism bias) 
for different prediction models (outcome was all cause 
dementia). Model 1 (M1) includes age, sex, educational 
attainment, physical function (impairment in activities of 
daily living), cognition function (mini-mental state 
examination, benton visual retention test, and digit span), 
health (cardiovascular disease, diabetes and systolic blood 
pressure), lifestyle (smoking and alcohol use), and 
apolipoprotein e4 status. Mri=magnetic resonance 
imaging, WMlv=white matter lesion volume
table 2 | results from Cox proportional hazards analyses with and without magnetic resonance imaging (Mri) variables added to risk prediction model 
incorporating only conventional risk variables (outcome was all cause dementia; n=1634)*
Hazard ratio (95% Ci)
Model 1 (M1)†
M1 + all 3 Mri  
variables
M1 + hippocampal 
volume
M1 + white matter 
lesion volume
M1 + whole 
brain volume
Age 2.77 (2.06 to 3.73) 2.26 (1.61 to 3.18) 2.07 (1.50 to 2.86) 2.87 (2.12 to 3.88) 2.49 (1.80 to 3.44)
Sex 0.90 (0.53 to 1.53) 0.84 (0.49 to 1.43) 0.90 (0.53 to 1.53) 0.85 (0.50 to 1.44) 0.94 (0.55 to 1.61)
Education 1.26 (0.99 to 1.59) 1.23 (0.97 to 1.56) 1.25 (0.99 to 1.58) 1.26 (0.99 to 1.59) 1.27 (1.01 to 1.61)
Impairment in activities of daily living 2.65 (1.44 to 4.86) 2.37 (1.28 to 4.41) 2.37 (1.28 to 4.38) 2.55 (1.38 to 4.71) 2.57 (1.39 to 4.74)
Mini-mental state examination 2.18 (1.28 to 3.71) 2.12 (1.23 to 3.64) 2.26 (1.32 to 3.87) 2.05 (1.20 to 3.50) 2.30 (1.35 to 3.92)
Benton visual retention test 2.77 (1.69 to 4.54) 2.76 (1.68 to 4.51) 2.71 (1.66 to 4.44) 2.72 (1.66 to 4.44) 2.72 (1.66 to 4.46)
Digit span 2.24 (1.34 to 3.74) 2.00 (1.19 to 3.34) 2.06 (1.23 to 3.44) 2.17 (1.30 to 3.63) 2.22 (1.33 to 3.70)
Smoking 1.18 (0.72 to 1.94) 1.08 (0.66 to 1.76) 1.13 (0.69 to 1.85) 1.15 (0.70 to 1.88) 1.19 (0.72 to 1.95)
Alcohol 0.92 (0.73 to 1.17) 0.87 (0.69 to 1.11) 0.88 (0.69 to 1.11) 0.90 (0.71 to 1.14) 0.91 (0.72 to 1.15)
Diabetes 1.25 (0.65 to 2.42) 1.41 (0.74 to 2.7) 1.35 (0.70 to 2.58) 1.28 (0.67 to 2.46) 1.22 (0.63 to 2.35)
Cardiovascular disease 0.97 (0.47 to 2.00) 0.94 (0.45 to 1.93) 0.94 (0.46 to 1.93) 0.91 (0.44 to 1.88) 0.98 (0.47 to 2.00)
Systolic blood pressure 1.00 (0.99 to 1.01) 1.00 (0.99 to 1.01) 1.00 (0.99 to 1.01) 1.00 (0.99 to 1.01) 1.00 (0.99 to 1.01)
Apolipoprotein 2.31 (1.54 to 3.45) 2.22 (1.48 to 3.32) 2.22 (1.49 to 3.32) 2.35 (1.57 to 3.50) 2.35 (1.57 to 3.52)
Hippocampal volume — 6.58e-6 (6.44e-8 to 6.72e-4) 3.37e-5 (7.77e-7 to 1.46e-3) — —
White matter lesion volume — 1.14 (0.86 to 1.52) — 1.38 (1.05 to 1.81) —
Whole brain volume — 1.07 (0.99 to 1.16) — — 0.94 (0.88 to 1.01)
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statistical indices that assess model performance, such 
as the integrated discrimination improvement index, 
showed improvement for the models incorporating 
 hippocampal volume or all three MRI variables. This 
result replicates findings of Zahuranec and colleagues, 
who found that exclusion of computed tomography vari-
ables from a model developed for the prediction of 30 day 
mortality after stroke had only a minimal impact on dis-
criminative performance measured with the area under 
the curve.47  In contrast, inclusion of computed tomogra-
phy variables did result in significant improvement in the 
integrated discrimination improvement index. Disparate 
results are caused by the calculation of each measure. 
The clinical relevance of this difference, in the presence 
of a non-significant change in the concordance index, 
within the framework of prediction of disease risk, how-
ever, is still unclear. Indeed, disparate results are often 
observed, leading to debate about the use of different 
metrics to assess model performance.48 49
We also found that Royston and Sauerbrei’s index of 
discrimination (D)44 and results from the decision curve 
analysis indicated improvement, in terms of prognostic 
separation and clinical utility, respectively, of the mod-
els incorporating hippocampal volume or all three MRI 
variables compared with the conventional risk model. 
The increase in net benefit has to be interpreted with 
caution because the decisional aspect of correctly iden-
tifying a person with dementia would require that there 
is also an effective preventative intervention or strategy 
available; however, a clear beneficial strategy currently 
does not exist. Further, the increase in net benefit could 
also be partly offset by potential inconveniences of the 
MRI imaging., When there might be requirements for 
increased sensitivity (such as because of increased risk 
of adverse effects in people with positive results on t
ab
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Fig 2 | Decision curve analysis for 10 year risk of all cause 
dementia for conventional risk model with and without the 
addition of all three Mri variables (white matter lesions 
volume, whole brain volume, and hippocampal volume). 
Model 1 (M1) includes age, sex, educational attainment, 
physical function (impairment in activities of daily living), 
cognition function (mini-mental state examination, benton 
visual retention test, and digit span), health (cardiovascular 
disease, diabetes and systolic blood pressure), lifestyle 
(smoking and alcohol use), and apolipoprotein e4 status. 
net benefit (dotted line) assumes all will develop dementia 
and theoretical beneficial action taken (“treat all”); solid 
horizontal line assumes none will develop dementia and no 
action (“treat none”)
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screening and the need to reduce false positive results), 
MRI variables might be appropriate. Before recommen-
dations can be made, however, further work replicating 
these results in other studies is needed.
Predicting alzheimer’s disease
Most cases of dementia (71%) were classified as proba-
ble/possible Alzheimer’s disease. A sensitivity analysis 
with Alzheimer’s disease as the outcome replicated the 
results of the models for prediction of all cause demen-
tia; a slight but non-significant increase in discrimina-
tory performance with inclusion of hippocampal 
volume or all three MRI variables to the conventional 
risk model. This supports other findings that have ques-
tioned whether the differences are large enough to war-
rant recommendations for MRI in population based 
samples.50 In contrast, and similar to the findings for all 
cause dementia, addition of all three magnetic imaging 
variables or hippocampal volume to the conventional 
risk model significantly improved reclassification, mea-
sured with the integrated discrimination index, and the 
decision curve analysis resulted in higher net benefit, 
however, as explained above, caution is required in the 
interpretation. These results suggest that MRI data 
could have some prognostic and clinical utility for pre-
dicting Alzheimer’s dementia. As we had only a limited 
number of cases with Alzheimer’s disease, however, 
these results should be interpreted with caution. Exten-
sion of these results to other cohorts focused on specific 
dementia subtypes and with postmortem confirmation 
of disease (and other Alzheimer’s disease biomarkers) 
is therefore needed.
Components of model for prediction of 
dementia risk 
There is no consensus in the literature regarding which 
variables best predict risk of incident dementia. In this 
paper we tested only conventional variables for risk that 
have previously been associated with dementia. Our 
aim was to test whether the inclusion of MRI data 
improved the discriminatory performance of a model 
incorporating variables that have been previously 
linked to dementia; it was not to develop a new model 
for dementia risk prediction. Increased age and poor 
cognition are strongly related to dementia. Importantly, 
none of the cognitive measures included in the model 
had been used for the final diagnosis of dementia, 
which was clinician based. Of note is the broad range of 
cognitive indicators required including measures of 
general functioning, memory, and non-memory ability. 
The results support findings suggesting that impaired 
performance in a single cognitive domain is not as effec-
tive at identifying individuals at risk of dementia as 
multi-domain deficits.51  Other relevant factors included 
educational attainment, impaired functional ability, 
and the apolipoprotein gene. Increased education has 
been previously linked to promoting “cognitive reserve” 
and is associated with decreased risk for dementia.52 
Declining functional ability, particularly in instrumen-
tal activities of daily living, is a hallmark of dementia 
diagnosis and is found in individuals in preclinical 
states, such as mild cognitive impairment.53  54  One or 
more of the apolipoprotein e4 alleles has been found to 
be a risk factor for dementia55 in both clinical and pop-
ulation based studies. Construction of risk prediction 
models with genetic variables, however, must proceed 
with caution and raises ethical concerns particularly 
around disclosure. Indeed, positive apolipoprotein e4 
status does not provide certainty of a risk of dementia.
strengths and limitations
The strengths of the study include the prospective popula-
tion based design, the large number of participants with 
MRI data, over 10 years follow-up, and the high level of 
detailed reporting of risk factors measured with 
 standardised methods. Several limitations should be 
table 4 | results from Cox proportional hazards analyses with and without Mri variables added to risk prediction model incorporating conventional risk 
variables only (outcome was alzheimer’s disease; n=1634)*
Hazard ratio (95% Ci)
Model 1 (M1)†
M1 + all 3 Mri  
variables
M1 + hippocampal  
volume
M1 + white matter 
lesion volume
M1 + whole brain 
volume
Age 2.72 (1.89 to 3.9) 2.15 (1.43 to 3.25) 1.92 (1.30 to 2.84) 2.79 (1.3 to 2.84) 2.48 (1.67 to 3.68)
Sex 1.02 (0.54 to 1.91) 0.93 (0.49 to 1.76) 1.02 (0.54 to 1.93) 0.96 (0.54 to 1.93) 1.07 (0.57 to 2.02)
Education 1.18 (0.90 to 1.56) 1.15 (0.87 to 1.51) 1.17 (0.89 to 1.54) 1.17 (0.89 to 1.54) 1.19 (0.90 to 1.57)
Impairment in activities of daily living 2.89 (1.39 to 6.01) 2.68 (1.28 to 5.60) 2.60 (1.24 to 5.45) 2.89 (1.24 to 5.45) 2.84 (1.36 to 5.93)
Mini-mental state examination 2.72 (1.48 to 4.99) 2.68 (1.43 to 5.01) 2.83 (1.52 to 5.26) 2.58 (1.52 to 5.26) 2.83 (1.54 to 5.20)
Benton visual retention test 2.06 (1.10 to 3.85) 2.07 (1.11 to 3.87) 2.03 (1.09 to 3.79) 2.03 (1.09 to 3.79) 2.03 (1.09 to 3.79)
Digit span 3.18 (1.81 to 5.58) 2.83 (1.60 to 5.01) 2.89 (1.64 to 5.08) 3.08 (1.64 to 5.08) 3.15 (1.80 to 5.53)
Smoking 1.43 (0.80 to 2.55) 1.24 (0.69 to 2.23) 1.34 (0.75 to 2.40) 1.39 (0.75 to 2.40) 1.43 (0.80 to 2.57)
Alcohol 0.85 (0.64 to 1.12) 0.79 (0.59 to 1.06) 0.79 (0.60 to 1.06) 0.82 (0.60 to 1.06) 0.84 (0.64 to 1.11)
Diabetes 1.16 (0.51 to 2.63) 1.29 (0.57 to 2.90) 1.20 (0.53 to 2.70) 1.14 (0.53 to 2.70) 1.12 (0.49 to 2.55)
Cardiovascular disease 0.67 (0.23 to 1.90) 0.64 (0.22 to 1.83) 0.61 (0.22 to 1.74) 0.61 (0.22 to 1.74) 0.66 (0.23 to 1.88)
Systolic blood pressure 1.00 (0.99 to 1.01) 1.00 (0.99 to 1.01) 1.00 (0.99 to 1.01) 1.00 (0.99 to 1.01) 1.00 (0.99 to 1.01)
APOE 2.25 (1.39 to 3.64) 2.09 (1.29 to 3.37) 2.12 (1.31 to 3.42) 2.29 (1.31 to 3.42) 2.30 (1.42 to 3.71)
Hippocampal volume — 3.88e-7 (1.90e-9 to 7.92e-5) 6.34e-6 (6.85e-8 to 5.86e-4) — —
White matter lesion volume — 1.07 (0.76 to 1.51) — 1.37 (0.99 to 1.89) —
Whole brain volume — 1.10 (1.01 to 1.20) — — 0.95 (0.88 to 1.03)
*Proportional hazards assumption confirmed for all models.
†Model 1 (M1) includes all non-magnetic imaging variables.
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 considered when interpreting our results. We aimed pri-
marily to test whether MRI derived variables previously 
associated with dementia could improve prediction of 
dementia in a population based setting, and, as such, 
findings might not generalise to other samples (such as 
clinical). The Three-City Study comprises volunteers, most 
of whom are white and generally have better global health 
than the rest of the population; this might also limit gener-
alisability of the results. Indeed, individuals who are able 
and willing to MRI tend to be relatively healthy (see find-
ings from the Rotterdam Study56 ). While this might 
explain the low occurrence of dementia (6.9%) in our t
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Fig 3 | C statistics (95% confidence intervals) (not adjusted 
for optimism bias) for different prediction models (outcome 
alzheimer’s disease). Model 1 (M1) included age, sex, 
educational attainment, physical function (impairment in 
activities of daily living), cognition function (mini-mental 
state examination, benton visual retention test, and digit 
span), health (cardiovascular disease, diabetes and 
systolic blood pressure), lifestyle (smoking and alcohol 
use), and apolipoprotein e4 status. Mri=magnetic 
resonance imaging. WMlv=white matter lesion volume
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Fig 4 | Decision curve analysis for 10 year risk of alzheimer’s 
disease for conventional risk model with and without 
addition of all three Mri variables (white matter lesions 
volume, whole brain volume, and hippocampal volume). 
Model 1 (M1) includes age, sex, educational attainment, 
physical function (impairment in activities of daily living), 
cognition function (mini-mental state examination, benton 
visual retention test, and digit span), health 
(cardiovascular disease, diabetes and systolic blood 
pressure), lifestyle (smoking and alcohol use) and 
apolipoprotein e4 status. net benefit (dotted line) assumes 
all will develop dementia and theoretical beneficial action 
taken (“treat all”); solid horizontal line assumes none will 
develop dementia and no action (“treat none”)
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study, we have no reason to believe that associations 
between MRI measures and dementia differ within this 
subgroup. These results needed to be replicated, however, 
across settings and in different populations (such as those 
with poor health and greater baseline risk of incident 
dementia), over different timeframes (such as a shorter 
follow-up time between scan and diagnosis of dementia), 
and in different ethnic groups. Bias could also have been 
introduced by the exclusion of participants with missing 
data who had poorer cognitive status at baseline, thus 
reducing the overall power of the study. Bootstrapping 
was undertaken to correct the concordance statistic for 
over-fitting, and the results indicated bias to be low. Power 
could have also have been reduced by us undertaking a 
complete case analysis. Results from the multiple imputa-
tion analysis, however, indicated consistency in findings 
in the reduced (complete case) and pooled (imputed) data-
sets. Additional studies with larger samples are needed to 
determine whether small positive changes in discrimina-
tion performance and reclassification of risk would show 
significant results. Small significant differences in predic-
tion, however, might not translate to improvement for the 
clinical setting. Finally, there is currently no consensus 
model for predicting risk of future dementia, and whether 
MRI enhances prediction in other dementia risk models 
requires testing. Lastly, there are discussions about the set 
up and utilisation of predictive models57 58; further evalua-
tion of this, however, is outside the scope of this study.
Clinical implications
Having a simple and accurate tool that could predict 
future risk of dementia would be beneficial not only to 
researchers (for example, to stratify samples for clinical 
trial recruitment) but, from a clinical perspective, might 
also help to provide stratified or personalised care. 
Indeed, while some of the variables included in the model 
are non-modifiable (such as age and apolipoprotein e4 
status), others are modifiable (such as educational attain-
ment, health, cognition, and functional ability). Here we 
show that in a population based setting, relatively simple 
measures can be used to predict risk with similar discrim-
ination performance to models that incorporate MRI find-
ings. This has important implications for the development 
of disease modifying or preventative strategies, as risk 
prediction with conventional factors, at least to some 
extent, seems sufficient in this setting.
In contrast, using other metrics to evaluate model per-
formance, we found that for both all cause dementia and 
Alzheimer’s disease, MRI variables could have some util-
ity in improving clinical decision making, prognostic 
separation, and classification. Appropriate choice of 
which model to use depends not only on the metric 
selected for evaluation but consideration of the ease of 
attaining the score and consequences of undertaking 
risk prediction.
Conclusions
Incorporation of complex and costly variables related to 
MRI does not seem to significantly improve perfor-
mance of a simple model that includes age, education, 
cognition, health, lifestyle, functional ability, and the 
apolipoprotein gene at the population level for all cause 
dementia (or Alzheimer’s disease). The results were not 
robust across the various metrics used for model evalu-
ation, however, including integrated discrimination 
improvement, the D statistic, or decision curve analy-
sis. The results suggest that routine MRI is not needed to 
predict risk of dementia in a population based setting, 
particularly in the first stages of screening such as dif-
ferentiating between those who are and are not at risk. 
Whether there is a subgroup of patients for whom brain 
MRI improves risk prediction will have to be determined 
in future studies. The results have important implica-
tions for avoiding unnecessary increases in cost for use 
of MRI in prediction of risk for dementia, especially in 
settings with limited technical and financial resources. 
Importantly, the results have implications for how we 
think about defining and operationalising models to 
predict risk of dementia, particularly in population 
based settings.
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